collaborate
collaborators
funding partners
affiliations
areas of collaboration
antigen discovery | development
adjuvant discovery | development |
delivery
product development
drug discovery
Chembio's long and successful history with IDRI is testimony to their superior antigen discovery skills and global network of expertise. This, combined with our mutual commitment to global health and a complementary approach in our research and development collaborations together, has produced outstanding results.
Lawrence Siebert, CEO, Chembio Diagnostic Systems, Inc.
| |
Drug Discovery
Our Drug Discovery Research Group focuses on identifying novel drug targets and new chemical entities as candidates to treat infectious diseases. Our current emphasis is on tuberculosis. We use innovative genetics tools to identify and validate novel drug targets in Mycobacterium tuberculosis. We also have dedicated BL3 facilities and extensive experience in the microbiology of M. tuberculosis.
When a disease target is identified from our discovery biology programs or from a collaborating laboratory, assays are developed and validated for high-throughput screening. Our robotic screening center can conduct screens based on a biochemical assay or against virulent M. tuberculosis in a BSL-3 facility. Promising hit compounds are then further tested and developed by our medicinal chemists with the aim of identifying lead compounds for preclinical testing.
We are interested in collaborating on new target identification projects, new screening assays, or new classes of potential anti-microbial compounds.
|
